000179750 001__ 179750
000179750 005__ 20240229145553.0
000179750 0247_ $$2doi$$a10.1016/j.euf.2022.04.001
000179750 0247_ $$2altmetric$$aaltmetric:127137249
000179750 0247_ $$2pmid$$apmid:35450799
000179750 037__ $$aDKFZ-2022-00877
000179750 082__ $$a610
000179750 1001_ $$aGrunewald, Camilla M.$$b0
000179750 245__ $$aUsing Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer: IMvigor010 and IMvigor011
000179750 260__ $$aAmsterdam$$bElsevier$$c2022
000179750 3367_ $$2DRIVER$$aarticle
000179750 3367_ $$2DataCite$$aOutput Types/Journal article
000179750 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1662034780_22790
000179750 3367_ $$2BibTeX$$aARTICLE
000179750 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000179750 3367_ $$00$$2EndNote$$aJournal Article
000179750 500__ $$a#LA:C130# / 2022 May;8(3):646-647 / Note
000179750 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000179750 588__ $$aDataset connected to CrossRef, Journals: inrepo02.dkfz.de
000179750 7001_ $$aNiegisch, Guenter$$b1
000179750 7001_ $$0P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aAlbers, Peter$$b2$$eLast author$$udkfz
000179750 773__ $$0PERI:(DE-600)2861750-2$$a10.1016/j.euf.2022.04.001$$gp. S2405456922000785$$n3$$p646-647$$tEuropean urology focus$$v8$$x2405-4569$$y2022
000179750 909CO $$ooai:inrepo02.dkfz.de:179750$$pVDB
000179750 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000179750 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000179750 9141_ $$y2022
000179750 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-09
000179750 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-09
000179750 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000179750 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000179750 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000179750 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000179750 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-11
000179750 9202_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000179750 9201_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000179750 980__ $$ajournal
000179750 980__ $$aVDB
000179750 980__ $$aI:(DE-He78)C130-20160331
000179750 980__ $$aUNRESTRICTED